Willibald Hochholzer started his career at the Heart Center in Bad Krozingen, where he initiated multiple studies focusing on pharmacodynamic response to antiplatelet strategies. Thereafter, he worked at the University Basel, Switzerland, on troponin based diagnosis algorithms for myocardial infarction that has become a key recommendation of current ESC guidelines. In 2009, he was invited for a Postdoc at the TIMI Study Group of Prof. Braunwald, Harvard Medical School, Boston, where he was working on several large randomized trials. After his return to the University Heart Center in Bad Krozingen, Germany, he became Associate Professor, head of clinical research and the interventional coronary unit, and initiated randomized trials focusing on antiplatelet strategies that received the Andreas-Gruentzig-award of the German Cardiac Society. In 2022, he became Director of the Department of Cardiovascular Medicine at the Klinikum Würzburg Mitte, Würzburg, Germany.